At ESMO, multiple teams showcased approaches aimed at EGFR-mutant non-small cell lung cancer after progression on AstraZeneca’s Tagrisso. The conference highlights intensifying competition among antibody-drug conjugates and next-step combinations focused on patients who develop resistance to frontline EGFR TKI therapy. SystImmune/Bristol Myers Squibb and Hengrui presented data on emerging EGFR-positioned strategies, underscoring how ADC makers are targeting post-TKI populations where efficacy and safety signals can meaningfully shift trial designs and future regulatory pathways.